Details for Patent: 8,299,078

Which drugs does patent 8,299,078 protect, and when does it expire?

Patent 8,299,078 protects FOLOTYN and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 8,299,078

Title:	Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
Abstract:	T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m.sup.2. In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m.sup.2 per dose.
Inventor(s):	O'Connor; Owen A. (Scarsdale, NY), Sirotnak; Francis M. (Hampton Bays, NY)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:	12/603,117
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,299,078
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 8,299,078

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-001	Sep 24, 2009		RX	Yes	No						TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009		RX	Yes	Yes						TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

International Family Members for US Patent 8,299,078

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E405272
Australia	2005249516
Brazil	PI0510895